3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 1/2
1
Status
Recruiting
2
Completed
2
Active not recruiting
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Dermatologic
2
Conditions
Breast Neoplasms
80
Neoplasms
61
Colorectal Neoplasms
42
Prostatic Neoplasms
41
Carcinoma, Non-Small-Cell Lung
35
Lung Neoplasms
31
Multiple Myeloma
23
Leukemia, Myeloid, Acute
23
Head and Neck Neoplasms
22
Pancreatic Neoplasms
15
Melanoma
15
Squamous Cell Carcinoma of Head and Neck
14
Precursor Cell Lymphoblastic Leukemia-Lymphoma
14
Ovarian Neoplasms
14
Neoplasm Metastasis
14
Carcinoma, Hepatocellular
14
Recurrence
13
Lymphoma, Non-Hodgkin
13
Stomach Neoplasms
12
Colonic Neoplasms
11
Uterine Cervical Neoplasms
10
Rectal Neoplasms
10
Lymphoma
10
Esophageal Neoplasms
10
Carcinoma, Renal Cell
10
Brain Neoplasms
10
Motor Activity
9
Kidney Neoplasms
9
Myelodysplastic Syndromes
8
Lymphoma, Large B-Cell, Diffuse
8
Interventions
pembrolizumab
1
lenvatinib
1
Blood Specimen Collection
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
Diabetes Mellitus, Insulin-Dependent, 12
×
30 days
×
Clear all
NCT04305054
2026-05-28
KEYMAKER-U02
Merck Sharp & Dohme LLC
Phase 1/2
Completed
335 enrolled
NCT04253080
2026-05-20
ENZYMELA
Assistance Publique - Hôpitaux de Paris
Phase NA
Completed
127 enrolled